Tiger Pharmaceuticals (stock code: 300347.SZ/3347.HK) is a contract research organization (CRO) focusing on providing professional services for clinical trials for new drug research and development, providing comprehensive clinical research for global pharmaceutical and medical device innovation companies. Services and solutions reduce R&D risks, shorten R&D cycles, save R&D funds, promote the marketization of products, and allow patients to use newer and better medical and medical products as soon as possible.

Tiger Pharmaceutical has established an integrated service platform covering the entire clinical research industry chain, serving the entire life cycle of drug and medical device product development, mainly including registration and regulatory affairs, clinical trials and clinical operations, data management and statistical analysis, Integrated clinical development technical services, medical devices and in vitro diagnostic reagents, post-market research and real-world research, etc.

Tiger Pharmaceuticals has also been a pioneer in global expansion of China's clinical CROs, and is currently operating in the Asia-Pacific region, North America and Europe. As of July 2021, Tiger Pharmaceutical has deployed Tiger employees in 39 countries around the world and established 17 overseas branches and offices. Since its establishment in 2004, Tiger Pharmaceutical has built a complete integrated and multi-faceted R&D service platform for clinical research of drugs and medical devices through the extension of its industrial chain and the construction of regional service capabilities. At the same time, Tiger Pharmaceutical has also continued to promote international expansion through investment, mergers and acquisitions, self-built teams, etc.